The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Lenalidomide in combination with gemcitabine in patients with untreated metastatic carcinoma of the pancreas: A Sarah Cannon Research Institute phase II trial.
H. Arkenau
No relevant relationships to disclose
J. R. Infante
Consultant or Advisory Role - Celgene (U)
J. C. Bendell
No relevant relationships to disclose
H. A. Burris
No relevant relationships to disclose
M. S. Rubin
No relevant relationships to disclose
D. M. Waterhouse
No relevant relationships to disclose
G. T. Jones
No relevant relationships to disclose
D. R. Spigel
Consultant or Advisory Role - Celgene (U)
J. D. Hainsworth
No relevant relationships to disclose